Advertisement
Research Article

The Impact of Retail-Sector Delivery of Artemether–Lumefantrine on Malaria Treatment of Children under Five in Kenya: A Cluster Randomized Controlled Trial

  • Beth P. Kangwana mail,

    bkangwana@nairobi.kemri-wellcome.org

    Affiliation: Malaria Public Health & Epidemiology Group, Kenya Medical Research Institute - Wellcome Trust Research Programme, Kenya

    X
  • Sarah V. Kedenge,

    Affiliation: Malaria Public Health & Epidemiology Group, Kenya Medical Research Institute - Wellcome Trust Research Programme, Kenya

    X
  • Abdisalan M. Noor,

    Affiliations: Malaria Public Health & Epidemiology Group, Kenya Medical Research Institute - Wellcome Trust Research Programme, Kenya, Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom

    X
  • Victor A. Alegana,

    Affiliation: Malaria Public Health & Epidemiology Group, Kenya Medical Research Institute - Wellcome Trust Research Programme, Kenya

    X
  • Andrew J. Nyandigisi,

    Affiliation: Division of Malaria Control, Ministry of Public Health and Sanitation, Nairobi, Kenya

    X
  • Jayesh Pandit,

    Affiliation: Pharmacy and Poisons Board, Nairobi, Kenya

    X
  • Greg W. Fegan,

    Affiliations: Malaria Public Health & Epidemiology Group, Kenya Medical Research Institute - Wellcome Trust Research Programme, Kenya, Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom

    X
  • James E. Todd,

    Affiliation: London School of Hygiene & Tropical Medicine, London, United Kingdom

    X
  • Simon Brooker,

    Affiliations: Malaria Public Health & Epidemiology Group, Kenya Medical Research Institute - Wellcome Trust Research Programme, Kenya, London School of Hygiene & Tropical Medicine, London, United Kingdom

    X
  • Robert W. Snow,

    Affiliations: Malaria Public Health & Epidemiology Group, Kenya Medical Research Institute - Wellcome Trust Research Programme, Kenya, Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom

    X
  • Catherine A. Goodman

    Affiliations: Malaria Public Health & Epidemiology Group, Kenya Medical Research Institute - Wellcome Trust Research Programme, Kenya, London School of Hygiene & Tropical Medicine, London, United Kingdom

    X
  • Published: May 31, 2011
  • DOI: 10.1371/journal.pmed.1000437

About the Authors

Beth P. Kangwana, Sarah V. Kedenge, Abdisalan M. Noor, Victor A. Alegana, Greg W. Fegan, Simon Brooker, Robert W. Snow, Catherine A. Goodman
Malaria Public Health & Epidemiology Group, Kenya Medical Research Institute - Wellcome Trust Research Programme, Kenya
Abdisalan M. Noor, Greg W. Fegan, Robert W. Snow
Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom
Andrew J. Nyandigisi
Division of Malaria Control, Ministry of Public Health and Sanitation, Nairobi, Kenya
Jayesh Pandit
Pharmacy and Poisons Board, Nairobi, Kenya
James E. Todd, Simon Brooker, Catherine A. Goodman
London School of Hygiene & Tropical Medicine, London, United Kingdom

Corresponding Author

Email: bkangwana@nairobi.kemri-wellcome.org

Competing Interests

RWS chairs the Novartis National Malaria Control Programme Managers "Best Practice Workshops" in Africa for which he receives an honorarium.

Author Contributions

ICMJE criteria for authorship read and met: BPK SVK AMN VAA AJN JP GWF JET SB RWS CAG. Agree with the manuscript's results and conclusions: BPK SVK AMN VAA AJN JP GWF JET SB RWS CAG. Designed the experiments/the study: BPK AJN GWF RWS CAG. Analyzed the data: BPK AMN AJN GWF JET CAG. Collected data/did experiments for the study: BPK SVK. Enrolled patients: BPK. Wrote the first draft of the paper: BPK. Contributed to the writing of the paper: BPK SVK AMN VAA AJN JP GWF JET SB RWS CAG. Ensured that regulatory requirements for Pharmacovigilance were met: JP. Advised on the interpretation of the study results: JET. Contributed to study design: SB. Reviewed all primary and secondary analysis: RWS.